Literature DB >> 23830672

Optimizing logistics for balloon-occluded retrograde transvenous obliteration (BRTO) of gastric varices by doing away with the indwelling balloon: concept and techniques.

Wael E Saad1, David B Nicholson.   

Abstract

Since the conception of balloon-occluded retrograde transvenous obliteration (BRTO) of gastric varices 25 years ago, the placement of an indwelling balloon for hours has been central to the BRTO procedure. Numerous variables and variations of the BRTO procedure have been described, including methods to reduce sclerosant, combining percutaneous transhepatic obliteration, varying sclerosant, and using multiple sclerosants within the same procedure. However, the consistent feature of BRTO has always remained the indwelling balloon. Placing an indwelling balloon over hours for the BRTO procedure is a logistical burden that taxes the interventional radiology team and hospital resources. Substituting the balloon with hardware (coils or Amplatzer vascular plugs [AVPs] or both) is technically feasible and its risks most likely correlate with gastrorenal shunt (GRS) size. The current authors use packed 0.018- or 0.035-in coils or both for small gastric variceal systems (GRS size A and B) and AVPs for GRS sizes up to size E (from size A-E). The current authors recommend an indwelling balloon (no hardware substitute) for very large gastric variceal system (GRS size F). Substituting the indwelling balloon for hardware in size F and potentially size E GRS can also be risky. The current article describes the techniques of placing up to 16-mm AVPs through balloon occlusion guide catheters and then deflating the balloon once it has been substituted with the AVPs. In addition, 22-mm AVPs can be placed through sheaths once the balloon occlusion catheters are removed to further augment the 16-mm Amplatzer occlusion. To date, there are no studies describing, let alone evaluating, the clinical feasibility of performing BRTO without indwelling balloons. The described techniques have been successfully performed by the current authors. However, the long-term safety and effectiveness of these techniques is yet to be determined.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amplatzers; BRTO; balloon occlusion; coils; ectopic varices; no balloon; obliteration; sclerosant; transvenous obliteration

Mesh:

Year:  2013        PMID: 23830672     DOI: 10.1053/j.tvir.2013.02.006

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  5 in total

Review 1.  Combining Transjugular Intrahepatic Portosystemic Shunt with Balloon-Occluded Retrograde Transvenous Obliteration or Augmenting TIPS with Variceal Embolization for the Management of Gastric Varices: An Evolving Middle Ground?

Authors:  Wael E Saad
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

Review 2.  Endovascular Treatment for Variceal Hemorrhage: TIPS, BRTO, and Combined Approaches.

Authors:  Andrew J Lipnik; Mithil B Pandhi; Ramzy C Khabbaz; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

3.  Balloon-occluded retrograde transvenous obliteration of gastric varix with multiple drainage veins performed with temporal occlusion of the pericardiacophrenic vein with a micro-balloon.

Authors:  Takuji Yamagami; Makoto Iida; Nobuko Tanitame; Rika Yoshimatsu; Chiaki Ono; Koji Waki; Keiji Tsuji; Kazuo Awai
Journal:  Acta Radiol Open       Date:  2015-08-25

4.  Vascular Plug Assisted Retrograde Transvenous Obliteration (PARTO) for Gastric Varix Bleeding Patients in the Emergent Clinical Setting.

Authors:  Taehwan Kim; Heechul Yang; Chun Kyon Lee; Gun Bea Kim
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

5.  The combination of balloon-assisted antegrade transvenous obliteration and transjugular intrahepatic portosystemic shunt for the management of cardiofundal varices hemorrhage.

Authors:  Jiacheng Liu; Chongtu Yang; Songjiang Huang; Chen Zhou; Qin Shi; Kun Qian; Songlin Song; Bin Xiong
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-05       Impact factor: 2.586

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.